Take­da signs op­tion deal for TKI in­hibitor; Enveda's $55M raise

Plus, news about IN8bio, Re­zo­lute, BeiGene and New­Bridge:

Take­da, As­cen­t­age ink op­tion deal: The deal in­volves a com­pound called olverem­bat­inib, which Take­da

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER